An interventional study of Lactoferrin in prevention of VAP and Control in Ventilator Associated Pneumonia, sponsored by Dalia Mohamed Salah. Recruiting at 1 site in Egypt. Open to participants aged 0 Days to 90 Days. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Dalia Mohamed Salah · Not applicable, Interventional, and Prevention
The aim of the study is to
Evaluate the Primary outcome of Lactoferrin on:
Sepsis, Feeding intolerance, Vomiting, Constipation or diarrhea
Incidence of VAP Duration of mechanical ventilation Duration of hospital stay
Randomised controlled trial
392 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 81 are open to participants now.
This study's planned enrollment of 120 is close to the median of 122 across 254 interventional studies indexed under Pneumonia, Ventilator-Associated.
Browse Pneumonia, Ventilator-Associated studies →This is the only study on the registry with Dalia Mohamed Salah as lead sponsor.
Counted across the registry records on this site, refreshed daily.
neonates requiring mechanical ventilation.
Gestational age:
Expected need for mechanical ventilation for ≥ (48hours)
Exclusion Criteria:
Congenital anomalies of the lung or airway.
Major congenital heart disease.
Proven early-onset sepsis at enrollment.
Severe perinatal asphyxia (e.g., Apgar \< 3 at 5 minutes or seizures).
Known contraindication or allergy to lactoferrin.
Severe gastrointestinal pathology (e.g., NEC stage II or higher).
Any condition deemed by the clinical team to interfere with study participation.
Neonates who will receive oral lactoferrin supplementation.
Dietary Supplement: Lactoferrin in prevention of VAP
who Will not receive
Other: Control
oral dose separate from feeds \[at a daily dose of 100mg/day\] via orogastric tube from first day of enrollment till time of successful extubation plus standard preventive measures of VAP; these include semi recumbent position, hand washing, suctioning when needed, endotracheal tube with subglottic secretion drainage, using heat and moisture exchanger filter, oral hygiene, changing of tubes only when needed and changing of ventilator circuit every 5 days.
They will receive standard preventive VAP strategies only.
Prevention of VAP
Diagnosis of VAP using the CDC/NHSN clinical and radiological criteria for neonatal ventilator-associated events. Outcome measured as the percentage (%) of enrolled neonates who develop VAP during NICU stay or up to 28 days of life.
Time frame: From enrollment until day 28 of life or NICU discharge, whichever occurs first.
Prevention of VAP
Incidence of ventilator-associated pneumonia during mechanical ventilation.
Time frame: during NICU stay
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pneumonia, Ventilator-Associated→